Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature.

Guy GP, Ekwueme DU.

Pharmacoeconomics. 2011 Oct;29(10):863-74. doi: 10.2165/11589300-000000000-00000. Review.

PMID:
21846158
2.

The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006.

Ekwueme DU, Guy GP Jr, Li C, Rim SH, Parelkar P, Chen SC.

J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S133-43. doi: 10.1016/j.jaad.2011.04.036.

3.
4.

Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany.

Stang A, Stausberg J, Boedeker W, Kerek-Bodden H, Jöckel KH.

J Eur Acad Dermatol Venereol. 2008 Jan;22(1):65-72. doi: 10.1111/j.1468-3083.2007.02334.x.

PMID:
18181975
5.

Years of potential life lost and productivity losses from male urogenital cancer deaths--United States, 2004.

Li C, Ekwueme DU, Rim SH, Tangka FK.

Urology. 2010 Sep;76(3):528-35. doi: 10.1016/j.urology.2010.04.030. Epub 2010 Jun 22. Review.

PMID:
20573389
6.

Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society.

Albert VA, Koh HK, Geller AC, Miller DR, Prout MN, Lew RA.

J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):308-10.

PMID:
2212128
7.

Melanoma-related mortality and productivity losses in the USA, 1990-2008.

Bristow BN, Casil J, Sorvillo F, Basurto-Dávila R, Kuo T.

Melanoma Res. 2013 Aug;23(4):331-5. doi: 10.1097/CMR.0b013e328361926c.

PMID:
23817202
8.

Health economic evaluation of non-melanoma skin cancer and actinic keratosis.

Higashi MK, Veenstra DL, Langley PC.

Pharmacoeconomics. 2004;22(2):83-94. Review.

PMID:
14731050
9.

Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2008 Nov 14;57(45):1226-8.

10.

Years of potential life lost and productivity costs due to premature cancer-related mortality in Iran.

Khorasani S, Rezaei S, Rashidian H, Daroudi R.

Asian Pac J Cancer Prev. 2015;16(5):1845-50.

11.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
12.

Health burden and costs of obesity and overweight in Germany.

Konnopka A, Bödemann M, König HH.

Eur J Health Econ. 2011 Aug;12(4):345-52. doi: 10.1007/s10198-010-0242-6. Epub 2010 Apr 18.

PMID:
20401679
13.

Annual smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 1997-2001.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2005 Jul 1;54(25):625-8.

14.

Screening for skin cancer.

Helfand M, Mahon SM, Eden KB, Frame PS, Orleans CT.

Am J Prev Med. 2001 Apr;20(3 Suppl):47-58. Review.

PMID:
11306232
15.

Economic consequences of HIV/AIDS in India.

Pandav CS, Anand K, Shamanna BR, Chowdhury S, Nath LM.

Natl Med J India. 1997 Jan-Feb;10(1):27-30.

PMID:
9069706
16.

A systematic review of low back pain cost of illness studies in the United States and internationally.

Dagenais S, Caro J, Haldeman S.

Spine J. 2008 Jan-Feb;8(1):8-20. doi: 10.1016/j.spinee.2007.10.005. Review.

PMID:
18164449
17.

[Smoking-attributable productivity loss in Germany--a partial sickness cost study based on the human capital potential method].

Wegner C, Gutsch A, Hessel F, Wasem J.

Gesundheitswesen. 2004 Jul;66(7):423-32. German.

PMID:
15314734
19.

Skin cancer is among the most costly of all cancers to treat for the Medicare population.

Housman TS, Feldman SR, Williford PM, Fleischer AB Jr, Goldman ND, Acostamadiedo JM, Chen GJ.

J Am Acad Dermatol. 2003 Mar;48(3):425-9.

PMID:
12637924
20.

Estimating the economic costs of skin cancer in New South Wales, Australia.

Doran CM, Ling R, Byrnes J, Crane M, Searles A, Perez D, Shakeshaft A.

BMC Public Health. 2015 Sep 23;15:952. doi: 10.1186/s12889-015-2267-3.

Supplemental Content

Support Center